Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.

Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Abstract Text:

    ryou fukushimaRyou Fukushima,susumu kanamoriSusumu Kanamori,masahiro hirashibaMasahiro Hirashiba,atsuko hishikawaAtsuko Hishikawa,ri-ich muranakaRi-Ich Muranaka,masako kanetoMasako Kaneto,kazuichi nakamuraKazuichi Nakamura,ikuo katoIkuo Kato,ryou fukushimaRyou Fukushima,susumu kanamoriSusumu Kanamori,masahiro hirashibaMasahiro Hirashiba,atsuko hishikawaAtsuko Hishikawa,ri-ich muranakaRi-Ich Muranaka,masako kanetoMasako Kaneto,kazuichi nakamuraKazuichi Nakamura,ikuo katoIkuo Kato,ryou fukushimaRyou Fukushima,susumu kanamoriSusumu Kanamori,masahiro hirashibaMasahiro Hirashiba,atsuko hishikawaAtsuko Hishikawa,ri-ich muranakaRi-Ich Muranaka,masako kanetoMasako Kaneto,kazuichi nakamuraKazuichi Nakamura,ikuo katoIkuo Kato,

    Leflunomide is an immunosuppressive agent that inhibits de novo synthesis of pyrimidine nucleotides and the activity of protein tyrosine kinase. This study examined the teratogenicity of Leflunomide in mice. Pregnant mice were treated orally with Leflunomide at a dose of 10, 30 or 70mg/kg/day from day 6 to 15 of pregnancy. At 70mg/kg, all embryos were resorbed and no live fetuses were detected. At 30mg/kg, Leflunomide reduced fetal viability, and increased the incidence of multiple external, skeletal and visceral malformations. Characteristic external malformations were neural tube defects, cleft palate and tail deformities. Limb malformations were observed in a small number of fetuses. Skeletal examinations revealed malformations of cervical to sacral vertebrae, ribs and sternebrae. In the viscerae, the main anomalies were membranous ventricular septum defect and persistent truncus arteriosus. The results of this study indicate that Leflunomide administered at 30mg/kg on days 6 to 15 of pregnancy can induce craniofacial malformations and deformities of the axial skeleton, heart and great vessels in mice.

    Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Publishing Authors By Initials

    r fukushimaR Fukushima,s kanamoriS Kanamori,m hirashibaM Hirashiba,a hishikawaA Hishikawa,ri muranakaRI Muranaka,m kanetoM Kaneto,k nakamuraK Nakamura,i katoI Kato,r fukushimaR Fukushima,s kanamoriS Kanamori,m hirashibaM Hirashiba,a hishikawaA Hishikawa,ri muranakaRI Muranaka,m kanetoM Kaneto,k nakamuraK Nakamura,i katoI Kato,r fukushimaR Fukushima,s kanamoriS Kanamori,m hirashibaM Hirashiba,a hishikawaA Hishikawa,ri muranakaRI Muranaka,m kanetoM Kaneto,k nakamuraK Nakamura,i katoI Kato,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Reproductive toxicology (Elmsford, N.Y.)

    VOLUME: 24

    Page Numbers: 310-6

    Journal Abbreviation: Reprod. Toxicol.

    ISSN: 0890-6238

    DAY: 18

    MONTH: 05

    YEAR: 2007

    Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8803591

    Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.

    AFFILIATION: Drug Safety Evaluation, Developmental Research Laboratories, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Reprod Toxicol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News